The effects of megestrol on related cytokines in patients with lung cancer complicated by sarcopenia
10.12354/j.issn.1000-8179.2024.20241243
- VernacularTitle:甲地孕酮对肺癌合并肌肉减少症患者相关细胞因子影响的探讨
- Author:
Liu YALAN
1
;
Cao WANQI
;
Zhang HUI
Author Information
1. 湖南省邵阳市中心医院肿瘤内科,湖南省邵阳市422000;天津医科大学肿瘤医院肺部肿瘤内科,国家肿瘤临床医学研究中心
- Publication Type:Journal Article
- Keywords:
megestrol;
sarcopenia;
cytokine
- From:
Chinese Journal of Clinical Oncology
2024;51(20):1039-1043
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To detect the increase in skeletal muscle mass after oral megestrol administration and its influence on the levels of four cytokines,analyze the relationship between cytokine expression and sarcopenia,and provide new insights for the management,curat-ive effect prediction,and early screening of lung cancer patients with sarcopenia. Methods:A total of 60 patients with lung cancer complic-ated by sarcopenia were recruited from The Central Hospital of Shaoyang between June 2023 and June 2024. They were randomly assigned into an experimental group (30 cases) and a control group (30 cases). Patient data,including age,sex,body mass index,skeletal muscle mass index (SMI),blood glucose,serum albumin,triglyceride levels,and the levels of four cytokines (IL-1β,IL-6,IFN-γ,and TNF-α),were recorded. The correlation between the four cytokines and sarcopenia was investigated after the intervention. Results:There was no significant differ-ence between the experimental and control groups except for the IL-1β level (P>0.05). The levels of the four cytokines decreased signific-antly on the 10th day of medication compared to days 10-25 (P<0.05). A positive correlation between the levels of the four cytokines at dif-ferent time points (P<0.05) was observed. After megestrol intervention,SMI values increased by 11.8％ from the baseline. Conclusions:Oral administration of megestrol can reduce the levels of cytokines IL-1β,IL-6,IFN-γ,and TNF-α while increasing the skeletal muscle mass to a certain extent. This suggests that megestrol may have positive therapeutic value in improving the prognosis and related clinical symptoms of patients with lung cancer and sarcopenia.
